The quality of any medicine is determined by its effectiveness, safety and ultimately the health outcome of a patient. If that quality is questionable, then any efforts and investment into public health systems and medicines regulatory systems will be compromised. MCQSD functions as a critical part of robust mechanisms for regulating medicines in CARICOM, in close cooperation with Member States, CARPHA Caribbean Regulatory System (CRS) and other partners such as PAHO/WHO. In June 2018, the Department established a post-market surveillance (PMS) programme for medicines circulating in the pharmaceutical markets of the Caribbean.
The post market surveillance programme focuses on two strategic components:
All CARPHA Member States are eligible to participate. The activities of the programme will involve:
A pre-determined list of medicines will be selected and revised annually, in collaboration with regional NMRAs, CRS and TECHPHARM. The procedures of the programme are subject to review during the annual evaluation of the programme.
The following criteria will be used to select the medicines for the post-market surveillance programme:
MQCSD has developed a Post-Marketing Surveillance Guide for Small Island Developing States. The Guide aims to
Copyright 2021 by The Caribbean Public Health Agency